Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice of Annual General Meeting

Valby, Denmark, 19 February 2018 –Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on:   Tuesday, 20 March 2018 at 10:00 am   The general meeting will be held at the offices of the Company at: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby   Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows:  1. Report of the Board of Directors on the Company's activities during the past year. 2. Presentation and adoption of the annual report. 3. Resolution on the appropriation of profit or

Nokia’s Chairman Risto Siilasmaa to deliver keynote about AI at MWC 2018 Finland pavilion

Nokia’s Chairman Risto Siilasmaa will be one of the keynote speakers at the Finland pavilion (3B10) during the Mobile World Congress 2018 (MWC 2018). This year, the Finland pavilion at MWC 2018 will host altogether 27 innovative Finnish tech SMEs, which will power up Barcelona with their groundbreaking digital expertize.Finland is ready to power up Barcelona. The Finland pavilion at MWC 2018 is a window to the future of technology with its abundant digital solutions, ranging from connectivity and 5G to AR and VR, Smart Mobility and IoT. Visit the pavilion and meet first-hand the

ADDvise receives order worth 2,7 MSEK

ADDvise Group AB’s (publ) subsidiary LabRum AB has signed an agreement with Arcona to deliver and assemble furniture and safety ventilation for laboratory facilities at Katedralskolan in Uppsala. The delivery is planned for February 2018 and the order is worth approximately 2,7 MSEK. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se  Important information:  This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February

Clas Ohlson launches smart news for the connected home

Now it will be easier to make your home somewhat smarter. With the Smart Plug from Clas Ohlson, your electronic home devices can be remotely controlled using a smartphone or tablet combined with the new Clas Ohlson Home app. In a nutshell, a great product at a competitive price.The Smart Plug remote control can control lights, fan heaters and even your coffee maker. An inbuilt advanced timer can also be controlled using the app. The timer can be used to manually input the time and intervals you want the power to come on and off, to make it look like someone is at home. The Smart Plug also

Indutrade issues two bond loans of in total SEK 1,000 million

Indutrade AB (publ) has issued two senior unsecured bonds of in total SEK 1,000 million with a tenor of five years.The first bond loan amounts to SEK 750 million and carries a floating interest rate of three months STIBOR +1.10%. The second bond loan amounts to SEK 250 million and carries a fixed rate of 1.75% annually. The transaction generated strong investor demand and the transaction was oversubscribed. The proceeds from the bond issues will be used for refinancing of existing bank loans and for general corporate purposes. Indutrade will apply for the new bonds to be listed on Nasdaq

RhoVac AB announces that all patients in company's clinical phase I/II study successfully completed their treatment phase with RV001.

RhoVac  AB ("RhoVac") announced today, 19th February 2018, that all patients successfully completed their treatment in company's clinical trial phase I/II study with RV001 cancer vaccine.RhoVac's drug candidate RV001, which targets metastatic cancer cells, is in clinical phase I/II development in patients with diagnosed prostate cancer. The cancer vaccine targets protein RhoC, which is highly over-expressed in metastatic cancer cells - no matter what form of cancer it is derived from. The goal of the RV001 project is to develop a cancer vaccine that prevents or limits the spread of cancer.

New shares of Caverion Corporation registered into the Trade Register

Caverion Corporation Stock exchange release 19 February 2018 at 9.45 a.m. EETNew shares of Caverion Corporation registered into the Trade Register A total of 3,800,000 new shares were subscribed for in Caverion Corporation’s share issue directed to the company itself without payment. All new shares have been entered into the Trade Register on 19 February 2018. After the registration, the total number of the shares in the Company is 129,396,092 shares, of which 4,312,328 shares are held by the Company. The new shares produce the right to dividends and other distribution of assets as

Invitation to presentation of Recipharm’s full year report for 2017 on the 22nd February

Recipharm will publish its full year report for January – December 2017 on 22 February at 7:45 am CET. The company invites investors, analysts and media to a web conference (in English) on 22 February at 10:00 am CET, where CEO Thomas Eldered and CFO Henrik Stenqvist will present and comment on the report as well as answer questions. The report will be available on Recipharm’s website www.recipharm.com/investor-relations from 7:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 22nd February. To participate in the web conference,

CST Global receives funding for the HELCATS, atomic clock project.

Sivers IMA Holding is pleased to announce that its subsidiary, CST Global (CST), has received £151,699 (approx. MSEK 1.7) from the British government to lead the HELCATS (High-power, phosphorous-based, DFB lasers for cold atom systems) project. The total project budget is £497,574, with government funding of nearly 80 percent. The project will run from March 2018 to February 2019.The HELCATS project will be managed by Dr. Olek Kowalski, Research Engineer at CST Global, alongside research partner, National Physical Laboratory Ltd. and academic partner, the University of Glasgow. “We are

Alipay payment solution in place - first milestone reached

The first milestone in the cooperation agreement between Appspotr and Novel Unicorn has been reached on schedule. That means that all the payment solutions are in place, which is prerequisite for reaching the sales targets specified in the agreement with Novel Unicorn.The first milestone in the agreement with Novel Unicorn was to reach a deal with at least one of two specified payment solutions providers. One of those specified was Alibaba and its payment solution Alipay, where a deal now has been reached. Alipay is one of China’s leading providers of mobile payment solutions and with close

Attendo AB (publ) – The Nomination Committee’s proposal prior to the AGM 2018

The Nomination Committee of Attendo AB (publ) proposes re-election of the board members Ulf Lundahl, Catarina Fagerholm, Tobias Lönnevall, Anssi Soila and Anitra Steen. The Nomination Committee proposes that Ulf Lundahl is re-elected as Chairman of the Board. Alf Göransson is proposed to be elected as new board member. The board members Mona Boström and Henrik Borelius informed that they are not available for re-election. Alf Göransson, born 1957 is the CEO of Securitas AB, an assignment he will leave during spring 2018 and Chairman of the Board in Loomis AB and board member of Hexpol AB

BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®

Bergen, Norway, 19 February 2018 – BerGenBio ASA  (OSE: BGBIO) announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.The Phase II trial (BGBC007) follows a two-stage design: it

AstraZeneca's IMFINZI approved for Stage III nsclc

This announcement contains inside information 19 February 2018 07:00 GMT US FDA APPROVES IMFINZI FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients

GHP expands its business in Copenhagen

GHP Gildhöj Privathospital is growing and is experiencing greater and greater demand from patients and customers. We have therefore decided to expand the business in order to meet the need and enable future growth.GHP Gildhöj Privathospital in Copenhagen has grown strongly in recent years as a result of great demand from insurance companies. The hospital focuses on patients with orthopaedic problems, but so that GHP can offer a more complete range of services in Denmark, the hospital has been expanded with a number of departments, including rheumatology and neurology. The business has

Tele2 IoT and Nokia empower enterprises with new model for global IoT deployments

Stockholm - Tele2 AB, (Tele2), (NASDAQ OMX Stockholm: TEL2 A and TEL2) and Nokia (publ) have signed a strategic partnership agreement to offer a global Internet of Things (IoT) connectivity solution for enterprises that simplifies the ecosystem for large multinational deployments and high bandwidth applications.The companies are entering a strategic and bilateral partnership centered around groundbreaking technologies from both companies, such as Nokia’s Worldwide IoT Network Grid (WING) and SIM technologies from Tele2 IoT. Based on the Nokia WING platform, Tele2 IoT will launch an

Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for its lead candidate, up to now referred to as Modufolin®. Arfolitixorin was recently accepted by  World Health Organization (WHO) as the International Non-proprietary Name (INN) for the active ingredient of Isofol's lead product Modufolin®.“We are delighted that the WHO has recognized the unique nature of our compound by accepting arfolitixorin as an INN. This is an important step towards bringing a new drug to market,” said Anders Rabbe, Chief Executive Officer at

Operations Update

ENQUEST PLC, 19 February 2018. OPERATIONS UPDATE.    2017 PRODUCTION IN LINE WITH GUIDANCE; MATERIAL PRODUCTION GROWTH EXPECTED IN 2018 EnQuest today provides an unaudited update on the Group's performance in 2017, together with an outlook for 2018 ahead of its 2017 Full Year Results, which will be announced on 20 March 2018. 2017 performance ·      Group production averaged 37,405 Boepd in 2017, in line with guidance. ·      Kraken first oil in Q2 2017, on schedule and under budget; achieved gross production rates of over 40,000 Bopd. ·      Operating expenditure

TOKMANNI GROUP CORPORATION: NOTICE TO THE GENERAL MEETING

TOKMANNI GROUP CORPORATION        Stock Exchange Release     19 February 9 am EETNotice is given to the shareholders of Tokmanni Group Corporation to the annual general meeting to be held on Wednesday 14 March 2018 at 10:00 a.m. at the Tokmanni’s administration and logistics centre at the address Isolammintie 1, 04600 Mäntsälä. The reception of persons who have registered for the meeting and the distribution of voting tickets as well as coffee service will commence at 9:00 a.m. A. Matters on the agenda of the general meeting  At the general meeting, the following matters will be

PRESS RELEASE: Faster and better development of biorefinery processes through modelling

In his dissertation, Senior Scientist and M.Sc. (Eng.) Kristian Melin of VTT Technical Research Centre of Finland has developed a modelling and evaluation method for identifying which biorefinery processes – of those being considered for development –will use raw materials most efficiently, reduce greenhouse gas emissions the most, or be most economical. The method can also accelerate the development of new bio-economic processes from laboratory to production scale. There has been public discussion of how much and what kind of wood raw material can be used sustainably for biorefinery

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given to the shareholders of Kesko Corporation that the Annual General Meeting will be held at Messukeskus Helsinki's Conference Centre, Messuaukio 1 (Conference Centre entrance), Helsinki, on Wednesday 11 April 2018 at 13.00 EET. The reception desks for those registered for the meeting will open and voting tickets will be provided starting from 12.00 EET. A. Items on the agenda of the General Meeting 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording

Ripasso Energy signs a Memorandum of Understanding to form a project financing company with capacity to acquire 72 PWR BLOK units

Two of Ripasso Energy’s shareholders and Ripasso Energy have signed a Memorandum of Understanding to form a new company (GenCo) to finance the acquisition of 72 of Ripasso Energy’s PWR BLOKs, priced at KEUR 500 per unit. The objective of the company is to acquire PWR BLOK units and then sell electricity on a per MWh-basis to large end-users in South Africa. Ripasso Energy will be responsible for client contact, EPC (Engineering, Procurement and Construction), O&M (Operations and Maintenance) and provide a cash credit line of up to MEUR 11 over 5 years to GenCo. Ripasso Energy will

AKERBP: Exploration success in PL340 near Alvheim

Aker BP is about to complete drilling of the Frosk exploration well 24/9-12 located near Alvheim in the North Sea. The well has proved oil. Preliminary analysis indicate a discovery size of 30-60 million barrels of oil equivalents (mmboe), which is significantly more than the company’s pre-drill estimates of 3-21 mmboe. The discovery also has a positive impact on the assessment of further exploration potential in the area. Frosk is located in PL340, which also contains the Bøyla field. Bøyla has been producing oil since 2015 through a subsea installation tied back to the Alvheim FPSO.

There are no items matching the current filter
There are no more items matching the current filter
Back to top